ITMCTR2100005149招募中未知
A multi-center, open-label, randomized controlled clinical trial study on the treatment of Delta novel coronavirus pneumonia (COVID-19) based on ''three-party'' syndrome differentiation and treatment
Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine)0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 —（—）
- 性别
- All
入选标准
- •1. Patients with mild and common new coronavirus pneumonia who meet the diagnostic criteria of the ''New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 8)'', with onset within 7 days.
- •2. Informed consent, volunteer experiment.
- •3. The process of obtaining informed consent should comply with GCP regulations.
排除标准
- •1. Aged <18 years;
- •2. Combined with serious primary heart, lung, liver, kidney, blood or diseases affecting their survival;
- •3. Creatinine and ALT/AST exceed 1.5 times the upper limit of normal;
- •4. Patients with mental illness, limited cognitive ability and disabled patients prescribed by law;
- •5. Pregnant or lactating patients;
- •6. Patients within 3 months or participating in clinical trials of other drugs.
研究者
相似试验
进行中（未招募）
不适用
A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylestradiol as beta-cyclodextrin clathrate and 3 mg drospirenone) compared to the conventional regimen of SH T00186D in the treatment of primary dysmenorrhea - SH T00186 in the treatment of primary dysmenorrheawomen suffering from primary dysmenorrheaEUCTR2006-004899-13-DEBayer Schering Pharma AG
进行中（未招募）
1 期
A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylestradiol as beta-cyclodextrin clathrate and 3 mg drospirenone) compared to the conventional regimen of SH T00186D in the treatment of primary dysmenorrhea - SH T00186 in the treatment of primary dysmenorrheawomen suffering from primary dysmenorrheaMedDRA version: 9.1Level: LLTClassification code 10036689Term: Primary dysmenorrhoeaEUCTR2006-004899-13-GBBayer Schering Pharma AG216
进行中（未招募）
不适用
A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis - ROSEosteopenia/osteoporosis in postmenopausal womenMedDRA version: 8.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2006-001703-11-DEovartis Pharma GmbH
招募中
2 期
Efficacy and safety of a carbohydrate-counting smartphone application in type 1 diabetesGlucose, insulin treatment, insulin secretionType 1 diabetesJPRN-jRCTs042210167Chujo Daisuke56
进行中（未招募）
1 期
A clinical trial where a change in medication can reduce the incidence of diabetes after renal transplantation.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 14.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-000451-13-SETransplant Institute, Sahlgrenska University Hospital223